Teva Pharma (TEVA) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 41.85 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $41.85 | 52 Week High | $66.55 | |||
| Open | $41.85 | 52 Week Low | $37.82 | |||
| Day High | $41.85 | P/E | N/A | |||
| Day Low | $41.85 | EPS | $0.00 | |||
| Volume | 72,740 | |||||
